Methantheline
Banthine (methantheline) is a small molecule pharmaceutical. Methantheline was first approved as Banthine on 1982-01-01. It is used to treat biliary dyskinesia, gastritis, irritable bowel syndrome, and pancreatitis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methantheline bromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BANTHINE | Shire | N-007390 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| biliary dyskinesia | EFO_0007169 | D001657 | — |
| gastritis | EFO_0000217 | D005756 | K29.7 |
| irritable bowel syndrome | EFO_0000555 | D043183 | K58 |
| pancreatitis | EFO_0000278 | D010195 | K85 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | 1 | 2 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 1 | — | — | 2 | 4 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular abnormalities | D018376 | EFO_0003848 | 1 | — | — | — | — | 1 | |
| Drug interactions | D004347 | 1 | — | — | — | — | 1 | ||
| Sexually transmitted diseases | D012749 | A50-A64 | 1 | — | — | — | — | 1 | |
| Depression | D003863 | F33.9 | 1 | — | — | — | — | 1 | |
| Affect | D000339 | 1 | — | — | — | — | 1 | ||
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Motivation | D009042 | 1 | — | — | — | — | 1 | ||
| Social behavior | D012919 | STY/T054 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Transcranial magnetic stimulation | D050781 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | METHANTHELINE |
| INN | methanthelinium bromide |
| Description | Methantheline is a member of xanthenes. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 5818-17-7 |
| RxCUI | 6821 |
| ChEMBL ID | CHEMBL1201264 |
| ChEBI ID | 6817 |
| PubChem CID | 4097 |
| DrugBank | DB00940 |
| UNII ID | 090519SAPF (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 332 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,842 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more